scholarly journals Neonatal Diabetes Caused by Activating Mutations in the Sulphonylurea Receptor

2013 ◽  
Vol 37 (3) ◽  
pp. 157 ◽  
Author(s):  
Peter Proks
2006 ◽  
Vol 14 (7) ◽  
pp. 824-830 ◽  
Author(s):  
Anna L Gloyn ◽  
Catherine Diatloff-Zito ◽  
Emma L Edghill ◽  
Christine Bellanné-Chantelot ◽  
Sylvie Nivot ◽  
...  

2006 ◽  
Vol 15 (11) ◽  
pp. 1793-1800 ◽  
Author(s):  
Peter Proks ◽  
Amanda L. Arnold ◽  
Jan Bruining ◽  
Christophe Girard ◽  
Sarah E. Flanagan ◽  
...  

2021 ◽  
Vol 5 (3) ◽  
pp. 106-116
Author(s):  
Eungu Kang ◽  
Lindsey Yoojin Chung ◽  
Yu Jin Kim ◽  
Kyung Eun Oh ◽  
Young-Jun Rhie

Monogenic diabetes mellitus, which is diabetes caused by a defect in a single gene that is associated with β cell function or insulin action, accounts for 1% to 6% of all pediatric diabetes cases. Accurate diagnosis is important, as the effective treatment differs according to genetic etiology in some types of monogenic diabetes: high-dose sulfonylurea treatment in neonatal diabetes caused by activating mutations in KCNJ11 or ABCC8; low-dose sulfonylurea treatment in HNF1A/HNF4A-diabetes; and no treatment in GCK diabetes. Monogenic diabetes should be suspected by clinicians for certain combinations of clinical features and laboratory results, and approximately 80% of monogenic diabetes cases are misdiagnosed as type 1 diabetes or type 2 diabetes. Here, we outline the types of monogenic diabetes and the clinical implications of genetic diagnosis.


2008 ◽  
Vol 52 (8) ◽  
pp. 1350-1355 ◽  
Author(s):  
Thais Della Manna ◽  
Claudilene Battistim ◽  
Vanessa Radonsky ◽  
Roberta D. Savoldelli ◽  
Durval Damiani ◽  
...  

Heterozygous activating mutations of KCNJ11 (Kir6.2) are the most common cause of permanent neonatal diabetes mellitus (PNDM) and several cases have been successfully treated with oral sulfonylureas. We report on the attempted transfer of insulin therapy to glibenclamide in a 4-year old child with PNDM and DEND syndrome, bearing a C166Y mutation in KCNJ11. An inpatient transition from subcutaneous NPH insulin (0.2 units/kg/d) to oral glibenclamide (1 mg/kg/d and 1.5 mg/kg/d) was performed. Glucose and C-peptide responses stimulated by oral glucose tolerance test (OGTT), hemoglobin A1c levels, the 8-point self-measured blood glucose (SMBG) profile and the frequency of hypoglycemia episodes were analyzed, before and during treatment with glibenclamide. Neither diabetes control nor neurological improvements were observed. We concluded that C166Y mutation was associated with a form of PNDM insensitive to glibenclamide.


2006 ◽  
Vol 355 (5) ◽  
pp. 456-466 ◽  
Author(s):  
Andrey P. Babenko ◽  
Michel Polak ◽  
Hélène Cavé ◽  
Kanetee Busiah ◽  
Paul Czernichow ◽  
...  

2016 ◽  
Vol 29 (12) ◽  
Author(s):  
Elif Ozsu ◽  
Dinesh Giri ◽  
Gulcan Seymen Karabulut ◽  
Senthil Senniappan

Abstract Neonatal diabetes is a rare form of monogenic diabetes characterised by persistent hyperglycaemia during the first 6–9 months of age. About half of the cases of neonatal diabetes are transient forms resulting from mutations in the genes in the imprinted region of chromosome 6q24 and the other half are permanent forms. Activating mutations in the potassium ATP (K


Sign in / Sign up

Export Citation Format

Share Document